Induct AS - Update on Care Pathway activities

Induct AS ("Induct" or the "Company") continues to advance the commercial deployment of Care Pathways in England. Current activities include progressing the planned subscription agreement with Portsmouth Hospitals University NHS Trust, extending the scope of the existing Severe Asthma Care Pathway, strengthening the evidence base for future adoption, expanding stakeholder engagement and evaluating funding opportunities.

Portsmouth subscription agreement:

Induct continues work towards establishing a subscription agreement with Portsmouth Hospitals University NHS Trust for Care Pathway. The proposed agreement would represent an important step in the Company's transition from the previous advertising-funded model to a subscription-based revenue model.

The contractual work includes both Portsmouth-specific requirements and matters relevant to future NHS deployments, including data protection, service delivery, liability and intellectual property rights. Induct is investing in this work to create a reusable contractual framework that can support future commercial agreements with NHS organisations.

The main commercial terms have largely been agreed. Completion remains subject to finalisation of the contractual documentation and approval by both parties.

Expansion of the Severe Asthma Care Pathway:

Induct and Portsmouth Hospitals University NHS Trust are also progressing work to expand the scope of the existing Severe Asthma Care Pathway.

Patients with severe asthma frequently have comorbidities and related inflammatory diseases that influence treatment decisions, particularly for patients receiving biologic therapies. As the use of biologic treatments expands, the need to manage these patients through an integrated clinical workflow is increasing.

Induct is therefore working with Portsmouth to extend the Severe Asthma Care Pathway to support additional biologic-treated patient groups and relevant comorbidities, including selected ear, nose and throat patient groups and patients with related inflammatory diseases. The objective is to build on the existing deployment by supporting a broader range of biologic-treated patients and associated clinical activities within the same platform.

Benefits realisation:

Induct is progressing work to strengthen the evidence base for the Severe Asthma Care Pathway through external evaluation and validation activities.

Portsmouth Hospitals University NHS Trust have reported a range of operational benefits from using the Severe Asthma Care Pathway, including improved pathway standardisation, information quality, service visibility and multidisciplinary team processes. The platform has also been associated with reduced administrative workload and increased MDT capacity, including the ability to assess more patients through multidisciplinary team processes.

To support future adoption and commercial deployment, Induct has initiated discussions with Health Innovation Oxford and Thames Valley on external evaluation and benefits realisation activities. The objective is to establish an independent and structured assessment of operational, clinical and economic outcomes, providing a stronger evidence base for NHS organisations considering adoption of the platform.

Broader stakeholder engagement:

Induct continues to engage with severe asthma specialist centres, patient organisations, NHS innovation and transformation stakeholders, and pharmaceutical companies active in respiratory and biologic treatment.

The purpose of this engagement is to support future adoption, strengthen the evidence base, understand the requirements of additional specialist services and identify opportunities for broader deployment within respiratory and related care pathways.

These activities build on Induct's previously communicated focus on engaging NHS organisations involved in innovation, digitalisation and healthcare transformation, while exploring selected extensions into related respiratory pathways.

Funding:

Induct continues to evaluate funding opportunities that could support the further development and adoption of Care Pathway. This includes opportunities associated with the Respiratory Transformation Partnership and other relevant funding programmes that may support pathway transformation, evidence generation and wider adoption.

Induct will update the market on material developments and milestones.

About Induct | www.induct.net Induct develops software that helps organisations deliver better services through digital workflows, collaboration and decision support. The Company's core business areas are digital care pathways, grant finder platforms and innovation management. Induct is listed on Euronext Growth Oslo under the ticker symbol INDCT.

For further information, please contact: Karl Erik Brøten CFO keb@induct.net